194594-62-2

Usage

Uses

Used in Organic Synthesis:
2-HYDROXY-1-BROMO-6-METHOXY-NAPHTHALENE is used as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its unique structure allows for versatile chemical reactions, making it a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-HYDROXY-1-BROMO-6-METHOXY-NAPHTHALENE is used as a precursor for the preparation of various pharmaceuticals. Its unique chemical properties enable the development of new drug candidates and therapies, contributing to the advancement of medicinal chemistry.
Used in Optical Brighteners and Dyes:
2-HYDROXY-1-BROMO-6-METHOXY-NAPHTHALENE is also used in the production of optical brighteners and dyes. Its ability to absorb and emit light in specific regions of the spectrum makes it a valuable component in the formulation of these color-enhancing agents, which are widely used in various industries such as textiles, paper, and plastics.
Used in Chemistry and Material Science:
In the field of chemistry and material science, 2-HYDROXY-1-BROMO-6-METHOXY-NAPHTHALENE is utilized for its unique properties and reactivity. Its potential applications in this field include the development of new materials with specific optical, electronic, or structural properties, as well as the study of its chemical behavior to gain insights into the broader understanding of naphthalene derivatives and their potential uses.

Upstream product

• 128-08-5 N-Bromosuccinimide 
• 5111-66-0 6-Methoxy-2-naphthol 
• 581-43-1 2.6-dihydroxynaphthalene 

Downstream Products

• 648905-66-2 4-{6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl}-N,N-dimethylbenzenesulfonamide 
• 862129-77-9 (+/-)-6-(4-methanesulfonyl-cyclohex-1-enyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol 
• 862130-04-9 6-(1,1-dioxo-hexahydro-1λ6-thiopyran-4-yl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol 
• 862129-85-9 6-(1,1-dioxo-1,2,3,6-tetrahydro-1λ6-thiopyran-4-yl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol 
• 861930-36-1 6-(3-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol 
• 862081-59-2 4-{6-hydroxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl}-N,N-dimethyl-benzamide 
• 648905-29-7 5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-6-[4-(propane-2-sulfonyl)-phenyl]-naphthalen-2-ol 
• 648904-79-4 6-(4-ethanesulfonyl-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol 
• 770708-13-9 4-{6-hydroxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl}-N,N-dimethylbenzenesulfonamide 
• 862129-75-7 (+/-)-1-(2-{4-[2-(4-methanesulfonyl-cyclohex-1-enyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine 
• 862129-82-6 1-(2-{4-[2-(1,1-dioxo-1,2,3,6-tetrahydro-1λ6-thiopyran-4-yl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine 
• 862130-05-0 6-(4-methanesulfonyl-cyclohexyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol 
• 862129-83-7 1-(2-{4-[2-(3,6-dihydro-2H-thiopyran-4-yl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine 
• 946077-40-3 C₃₀H₂₉NO₃F₂ 

Relevant academic research and scientific papers

TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND

Disclosed is a series of tricyclic substituted piperidine dione compounds, and applications thereof in the preparation of medicines for treating diseases related to CRBN protein; specifically disclosed are the derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Enantioselective Ni-Catalyzed Electrochemical Synthesis of Biaryl Atropisomers

A scalable enantioselective nickel-catalyzed electrochemical reductive homocoupling of aryl bromides has been developed, affording enantioenriched axially chiral biaryls in good yield under mild conditions using electricity as a reductant in an undivided cell. Common metal reductants such as Mn or Zn powder resulted in significantly lower yields in the absence of electric current under otherwise identical conditions, underscoring the enhanced reactivity provided by the combination of transition metal catalysis and electrochemistry.

Modular Assembly of Spirocarbocyclic Scaffolds through Pd0-Catalyzed Intermolecular Dearomatizing [2+2+1] Annulation of Bromonaphthols with Aryl Iodides and Alkynes

A novel palladium(0)-catalyzed dearomatizing [2+2+1] spiroannulation of 1-bromo-2-naphthols with aryl iodides and alkynes was developed for the rapid assembly of spiro[indene-1,1′-naphthalen]-2′-ones. This three-component cascade reaction was realized thr

A scalable and expedient route to 1-Aza[6]helicene derivatives and its subsequent application to a chiral-relay asymmetric strategy

A rapid route to diversely functionalized 1-aza[6]helicenes has been achieved via the development of a copper-mediated cross-coupling reaction, followed by PtCl4-catalyzed cycloisomerization. Not only does this method allow access to these func

SELECTIVE ESTROGEN RECEPTOR MODULATOR

The present invention is directed to a compound of the formula (A): or a pharmaceutically acceptable salt thereof; and also to compounds of formula (I): or a pharmaceutically acceptable salt thereof.

Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety

Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation.

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats

The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors α and β (ERα and ERβ, respectively) and is a potent uterine

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.

SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS

The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.